Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
about
Highlight: BRCA1 and BRCA2 proteins in breast cancerA combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentDeregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerImpact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersMultimodality breast cancer screening in women with a familial or genetic predisposition.Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer.Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsLymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.BRCA1 functions as a breast stem cell regulator.Novel genetic markers of breast cancer survival identified by a genome-wide association study.Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice.Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experienceHigh-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistanceSurvival in Norwegian BRCA1 mutation carriers with breast cancer.BRCA1 promoter methylation is associated with increased mortality among women with breast cancerp27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysisEpigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target.Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
P2860
Q24307401-7A28446A-A0F4-45E5-9948-E0598CDD969EQ24803679-99184B06-B5EB-4FC4-8D34-F5BDFBAD771DQ24803723-EE4E9091-CE90-4AB7-B959-FDE80D906D58Q30764147-CDC8531E-586E-4D61-8C66-01DEEC35E3FEQ33829394-5EAB7136-9B6E-46E7-8223-CC7D493A4DD8Q33863531-5A8D2C08-BC02-40FE-85BB-C9DA01049F98Q33894579-732B4F1F-55DA-42CD-ADE3-15DFCA4C9C99Q33903965-5BB3392F-1CC3-49EA-BCE1-8E6A992F5263Q33965570-E79C6126-5054-4001-B3F2-E8B982EE0938Q34288214-5B052897-FDED-46BA-B889-07ACC633D86FQ34520664-FFD95CBB-FFB5-4EE0-A7DE-A9DE1FBE2FECQ35039478-462E9534-28C8-4647-BFF4-B3E913FACD61Q35100315-5D89D83A-A326-4305-AAA4-15DDC9984F0FQ35157568-F0C4B824-4EE6-4D35-B730-327D0DCA6C19Q35224593-3AEFD53C-2AE3-443E-85B7-1C2DF8CFED10Q35559914-1BEF1231-55DA-46A7-BA7D-A40C4A604A2AQ35803492-502788FF-F2A3-497C-B9E6-D0CC3E4F5C4FQ36175746-2A5F8111-D938-4DE4-AFCE-D27235F5DE72Q36393316-6F798AF9-E220-4E79-975A-6A877074B983Q36920416-E562AF09-B003-44CE-85C6-88FE67C1C073Q37109252-875B9129-98A9-4E86-AB21-5930EA668504Q37182133-08987841-4DF3-4932-A74A-ED45C40AC019Q37219292-7451BC7E-8DFA-4DF2-84F9-231B311B9532Q37295292-C9F869E2-9523-49F0-A28D-FD82D5A94144Q37324446-C71FA549-24DE-4EB2-9FB7-DD08142103E7Q37818287-E072BC96-ADED-485D-9C49-19D726BBBFD8Q40543164-85DCB2AA-6FA2-471A-8526-0290342AC4C8Q44202163-1F09AC33-BBD0-4FF1-9492-34FFFFCC953EQ49210867-334C1887-7948-4BD4-921A-A251DA610A34Q50978039-01CD7F83-BA4F-42FF-A442-915CE37C827D
P2860
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Germline BRCA1/2 mutations and ...... t outcome after breast cancer.
@ast
Germline BRCA1/2 mutations and ...... t outcome after breast cancer.
@en
type
label
Germline BRCA1/2 mutations and ...... t outcome after breast cancer.
@ast
Germline BRCA1/2 mutations and ...... t outcome after breast cancer.
@en
prefLabel
Germline BRCA1/2 mutations and ...... t outcome after breast cancer.
@ast
Germline BRCA1/2 mutations and ...... t outcome after breast cancer.
@en
P2093
P1476
Germline BRCA1/2 mutations and ...... ct outcome after breast cancer
@en
P2093
J S Brunet
J Slingerland
P O Chappuis
P304
P356
10.1200/JCO.2000.18.24.4045
P407
P577
2000-12-01T00:00:00Z